NMDAR2A Antibody - #DF7955
Product: | NMDAR2A Antibody |
Catalog: | DF7955 |
Description: | Rabbit polyclonal antibody to NMDAR2A |
Application: | WB IHC IF/ICC |
Reactivity: | Human, Mouse, Rat |
Prediction: | Pig, Bovine, Sheep |
Mol.Wt.: | 165 kDa; 165kD(Calculated). |
Uniprot: | Q12879 |
RRID: | AB_2841353 |
Product Info
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
Cite Format: Affinity Biosciences Cat# DF7955, RRID:AB_2841353.
Fold/Unfold
EPND; FESD; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; Glutamate receptor; Glutamate receptor ionotropic N methyl D aspartate 2A; GRIN 2A; GRIN2A; hNR2A; LKS; N methyl D aspartate receptor channel, subunit epsilon 1; N Methyl D Aspartate Receptor Subtype 2A; N methyl D aspartate receptor subunit 2A; N-methyl D-aspartate receptor subtype 2A; NMDA receptor subtype 2A; NMDAR 2A; NMDAR2A; NMDE1_HUMAN; NR2A; OTTHUMP00000160135; OTTHUMP00000174531;
Immunogens
- Q12879 NMDE1_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MGRVGYWTLLVLPALLVWRGPAPSAAAEKGPPALNIAVMLGHSHDVTERELRTLWGPEQAAGLPLDVNVVALLMNRTDPKSLITHVCDLMSGARIHGLVFGDDTDQEAVAQMLDFISSHTFVPILGIHGGASMIMADKDPTSTFFQFGASIQQQATVMLKIMQDYDWHVFSLVTTIFPGYREFISFVKTTVDNSFVGWDMQNVITLDTSFEDAKTQVQLKKIHSSVILLYCSKDEAVLILSEARSLGLTGYDFFWIVPSLVSGNTELIPKEFPSGLISVSYDDWDYSLEARVRDGIGILTTAASSMLEKFSYIPEAKASCYGQMERPEVPMHTLHPFMVNVTWDGKDLSFTEEGYQVHPRLVVIVLNKDREWEKVGKWENHTLSLRHAVWPRYKSFSDCEPDDNHLSIVTLEEAPFVIVEDIDPLTETCVRNTVPCRKFVKINNSTNEGMNVKKCCKGFCIDILKKLSRTVKFTYDLYLVTNGKHGKKVNNVWNGMIGEVVYQRAVMAVGSLTINEERSEVVDFSVPFVETGISVMVSRSNGTVSPSAFLEPFSASVWVMMFVMLLIVSAIAVFVFEYFSPVGYNRNLAKGKAPHGPSFTIGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEFVDQVTGLSDKKFQRPHDYSPPFRFGTVPNGSTERNIRNNYPYMHQYMTKFNQKGVEDALVSLKTGKLDAFIYDAAVLNYKAGRDEGCKLVTIGSGYIFATTGYGIALQKGSPWKRQIDLALLQFVGDGEMEELETLWLTGICHNEKNEVMSSQLDIDNMAGVFYMLAAAMALSLITFIWEHLFYWKLRFCFTGVCSDRPGLLFSISRGIYSCIHGVHIEEKKKSPDFNLTGSQSNMLKLLRSAKNISSMSNMNSSRMDSPKRAADFIQRGSLIMDMVSDKGNLMYSDNRSFQGKESIFGDNMNELQTFVANRQKDNLNNYVFQGQHPLTLNESNPNTVEVAVSTESKANSRPRQLWKKSVDSIRQDSLSQNPVSQRDEATAENRTHSLKSPRYLPEEMAHSDISETSNRATCHREPDNSKNHKTKDNFKRSVASKYPKDCSEVERTYLKTKSSSPRDKIYTIDGEKEPGFHLDPPQFVENVTLPENVDFPDPYQDPSENFRKGDSTLPMNRNPLHNEEGLSNNDQYKLYSKHFTLKDKGSPHSETSERYRQNSTHCRSCLSNMPTYSGHFTMRSPFKCDACLRMGNLYDIDEDQMLQETGNPATGEQVYQQDWAQNNALQLQKNKLRISRQHSYDNIVDKPRELDLSRPSRSISLKDRERLLEGNFYGSLFSVPSSKLSGKKSSLFPQGLEDSKRSKSLLPDHTSDNPFLHSHRDDQRLVIGRCPSDPYKHSLPSQAVNDSYLRSSLRSTASYCSRDSRGHNDVYISEHVMPYAANKNNMYSTPRVLNSCSNRRVYKKMPSIESDV
Predictions
Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.
High(score>80) Medium(80>score>50) Low(score<50) No confidence
PTMs - Q12879 As Substrate
Site | PTM Type | Enzyme | Source |
---|---|---|---|
C87 | S-Nitrosylation | Uniprot | |
T104 | Phosphorylation | Uniprot | |
T120 | Phosphorylation | Uniprot | |
S274 | Phosphorylation | Uniprot | |
S278 | Phosphorylation | Uniprot | |
S280 | Phosphorylation | Uniprot | |
Y281 | Phosphorylation | Uniprot | |
C320 | S-Nitrosylation | Uniprot | |
Y393 | Phosphorylation | Uniprot | |
C399 | S-Nitrosylation | Uniprot | |
T470 | Phosphorylation | Uniprot | |
S719 | Phosphorylation | Uniprot | |
Y730 | Phosphorylation | Uniprot | |
Y737 | Phosphorylation | Uniprot | |
T749 | Phosphorylation | Uniprot | |
K880 | Methylation | Uniprot | |
S900 | Phosphorylation | Uniprot | |
S905 | Phosphorylation | Uniprot | |
S906 | Phosphorylation | Uniprot | |
S908 | Phosphorylation | Uniprot | |
S912 | Phosphorylation | Uniprot | |
S913 | Phosphorylation | Uniprot | |
S917 | Phosphorylation | Uniprot | |
S929 | Phosphorylation | Uniprot | |
K938 | Ubiquitination | Uniprot | |
Y943 | Phosphorylation | P06241 (FYN) | Uniprot |
S1048 | Phosphorylation | Uniprot | |
Y1105 | Phosphorylation | P06241 (FYN) | Uniprot |
Y1118 | Phosphorylation | P06241 (FYN) | Uniprot |
S1163 | Phosphorylation | Uniprot | |
T1164 | Phosphorylation | Uniprot | |
S1179 | Phosphorylation | Uniprot | |
Y1184 | Phosphorylation | P12931 (SRC) | Uniprot |
Y1187 | Phosphorylation | P06241 (FYN) | Uniprot |
S1232 | Phosphorylation | Uniprot | |
Y1246 | Phosphorylation | P06241 (FYN) | Uniprot |
Y1267 | Phosphorylation | P06241 (FYN) , P12931 (SRC) | Uniprot |
S1291 | Phosphorylation | Uniprot | |
Y1325 | Phosphorylation | P06241 (FYN) , P12931 (SRC) | Uniprot |
Y1387 | Phosphorylation | Uniprot | |
S1416 | Phosphorylation | Uniprot | |
Y1423 | Phosphorylation | P12931 (SRC) | Uniprot |
Research Backgrounds
Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+). Sensitivity to glutamate and channel kinetics depend on the subunit composition; channels containing GRIN1 and GRIN2A have higher sensitivity to glutamate and faster kinetics than channels formed by GRIN1 and GRIN2B. Contributes to the slow phase of excitatory postsynaptic current, long-term synaptic potentiation, and learning (By similarity).
Cell projection>Dendritic spine. Cell membrane>Multi-pass membrane protein. Cell junction>Synapse. Cell junction>Synapse>Postsynaptic cell membrane>Multi-pass membrane protein. Cytoplasmic vesicle membrane.
Note: Expression at the dendrite cell membrane and at synapses is regulated by SORCS2 and the retromer complex.
Heterotetramer. Forms heterotetrameric channels composed of two zeta subunits (GRIN1), and two epsilon subunits (GRIN2A, GRIN2B, GRIN2C or GRIN2D) (in vitro). Can also form heterotetrameric channels that contain at least one zeta subunit (GRIN1), at least one epsilon subunit, plus GRIN3A or GRIN3B. In vivo, the subunit composition may depend on the expression levels of the different subunits. Found in a complex with GRIN1, GRIN3A and PPP2CB (By similarity). Found in a complex with GRIN1 and GRIN3B (By similarity). Interacts with AIP1 (By similarity). Interacts with HIP1 and NETO1. Interacts with SNX27 (via PDZ domain); the interaction is required for recycling to the plasma membrane when endocytosed and prevent degradation in lysosomes (By similarity). Interacts with PDZ domains of PATJ and DLG4. Interacts with LRFN2 (By similarity). Interacts with RPH3A and DLG4; this ternary complex regulates NMDA receptor composition at postsynaptic membranes (By similarity). Interacts with SORCS2 (By similarity). Interacts with ARC; preventing ARC oligomerization (By similarity).
Contains an N-terminal domain, a ligand-binding domain and a transmembrane domain. Agonist binding to the extracellular ligand-binding domains triggers channel gating.
A hydrophobic region that gives rise to the prediction of a transmembrane span does not cross the membrane, but is part of a discontinuously helical region that dips into the membrane and is probably part of the pore and of the selectivity filter.
Belongs to the glutamate-gated ion channel (TC 1.A.10.1) family. NR2A/GRIN2A subfamily.
Research Fields
· Environmental Information Processing > Signal transduction > Ras signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > Rap1 signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > Calcium signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > cAMP signaling pathway. (View pathway)
· Environmental Information Processing > Signaling molecules and interaction > Neuroactive ligand-receptor interaction.
· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.
· Human Diseases > Neurodegenerative diseases > Amyotrophic lateral sclerosis (ALS).
· Human Diseases > Substance dependence > Cocaine addiction.
· Human Diseases > Substance dependence > Amphetamine addiction.
· Human Diseases > Substance dependence > Alcoholism.
· Human Diseases > Immune diseases > Systemic lupus erythematosus.
· Organismal Systems > Environmental adaptation > Circadian entrainment.
· Organismal Systems > Nervous system > Long-term potentiation.
· Organismal Systems > Nervous system > Glutamatergic synapse.
· Organismal Systems > Nervous system > Dopaminergic synapse.
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.